Found: 44
Select item for more details and to access through your institution.
Implementing Ac-225 labelled radiopharmaceuticals: practical considerations and (pre-)clinical perspectives.
- Published in:
- EJNMMI Radiopharmacy & Chemistry, 2024, v. 9, n. 1, p. 1, doi. 10.1186/s41181-024-00239-1
- By:
- Publication type:
- Article
The Balance Between the Therapeutic Efficacy and Safety of [<sup>177</sup>Lu]Lu-NeoB in a Preclinical Prostate Cancer Model.
- Published in:
- Molecular Imaging & Biology, 2024, v. 26, n. 1, p. 114, doi. 10.1007/s11307-023-01851-4
- By:
- Publication type:
- Article
Evaluation of the tolerability and safety of [<sup>225</sup>Ac]Ac-PSMA-I&T in patients with metastatic prostate cancer: a phase I dose escalation study.
- Published in:
- BMC Cancer, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12885-024-11900-y
- By:
- Publication type:
- Article
Improved postprocessing of dynamic glucose-enhanced CEST MRI for imaging brain metastases at 3 T.
- Published in:
- European Radiology Experimental, 2023, v. 7, n. 1, p. 1, doi. 10.1186/s41747-023-00390-5
- By:
- Publication type:
- Article
Replacing Lu-177 with Tb-161 in DOTA-TATE and PSMA-617 therapy: potential dosimetric implications for activity selection.
- Published in:
- EJNMMI Physics, 2023, v. 10, n. 1, p. 1, doi. 10.1186/s40658-023-00589-w
- By:
- Publication type:
- Article
[ 212 Pb]Pb-eSOMA-01: A Promising Radioligand for Targeted Alpha Therapy of Neuroendocrine Tumors.
- Published in:
- Pharmaceuticals (14248247), 2023, v. 16, n. 7, p. 985, doi. 10.3390/ph16070985
- By:
- Publication type:
- Article
First preclinical evaluation of [<sup>225</sup>Ac]Ac-DOTA-JR11 and comparison with [<sup>177</sup>Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs.
- Published in:
- EJNMMI Radiopharmacy & Chemistry, 2023, v. 8, n. 1, p. 1, doi. 10.1186/s41181-023-00197-0
- By:
- Publication type:
- Article
DNA-PKcs inhibitors sensitize neuroendocrine tumor cells to peptide receptor radionuclide therapy in vitro and in vivo.
- Published in:
- Theranostics, 2023, v. 13, n. 10, p. 3117, doi. 10.7150/thno.82963
- By:
- Publication type:
- Article
In Vivo Efficacy Testing of Peptide Receptor Radionuclide Therapy Radiosensitization Using Olaparib.
- Published in:
- Cancers, 2023, v. 15, n. 3, p. 915, doi. 10.3390/cancers15030915
- By:
- Publication type:
- Article
Radiolabeling and quality control of therapeutic radiopharmaceuticals: optimization, clinical implementation and comparison of radio-TLC/HPLC analysis, demonstrated by [<sup>177</sup>Lu]Lu-PSMA.
- Published in:
- EJNMMI Radiopharmacy & Chemistry, 2022, v. 7, n. 1, p. 1, doi. 10.1186/s41181-022-00181-0
- By:
- Publication type:
- Article
Safety of [<sup>177</sup>Lu]Lu-NeoB treatment: a preclinical study characterizing absorbed dose and acute, early, and late organ toxicity.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2022, v. 49, n. 13, p. 4440, doi. 10.1007/s00259-022-05926-2
- By:
- Publication type:
- Article
Advances in 177 Lu-PSMA and 225 Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer.
- Published in:
- Pharmaceutics, 2022, v. 14, n. 10, p. N.PAG, doi. 10.3390/pharmaceutics14102166
- By:
- Publication type:
- Article
In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2022, v. 49, n. 11, p. 3627, doi. 10.1007/s00259-022-05821-w
- By:
- Publication type:
- Article
Correction to: In vitro dose effect relationships of actinium‑225‑ and lutetium‑177‑labeled PSMA‑I&T.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for Prostate Cancer Treatment.
- Published in:
- International Journal of Molecular Sciences, 2022, v. 23, n. 14, p. 8037, doi. 10.3390/ijms23148037
- By:
- Publication type:
- Article
Improved Multimodal Tumor Necrosis Imaging with IRDye800CW-DOTA Conjugated to an Albumin-Binding Domain.
- Published in:
- Cancers, 2022, v. 14, n. 4, p. 861, doi. 10.3390/cancers14040861
- By:
- Publication type:
- Article
In Vivo Evaluation of Gallium-68-Labeled IRDye800CW as a Necrosis Avid Contrast Agent in Solid Tumors.
- Published in:
- Contrast Media & Molecular Imaging, 2021, p. 1, doi. 10.1155/2021/2853522
- By:
- Publication type:
- Article
Imaging inflammation in atherosclerotic plaques, targeting SST<sub>2</sub> with [<sup>111</sup>In]In-DOTA-JR11.
- Published in:
- Journal of Nuclear Cardiology, 2021, v. 28, n. 6, p. 2506, doi. 10.1007/s12350-020-02046-y
- By:
- Publication type:
- Article
GRPr antagonist <sup>68</sup>Ga‐SB3 PET/CT‐imaging of primary prostate cancer in therapynaive patients.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.120.258814
- By:
- Publication type:
- Article
GRPr antagonist <sup>68</sup>Ga‐SB3 PET/CT‐imaging of primary prostate cancer in therapy‐ naive patients.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.120.258814
- By:
- Publication type:
- Article
GRPr antagonist <sup>68</sup>Ga‐SB3 PET/CT‐imaging of primary prostate cancer in therapy‐ naive patients.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.120.258814
- By:
- Publication type:
- Article
GRPr antagonist <sup>68</sup>Ga-SB3 PET/CT-imaging of primary prostate cancer in therapy-naive patients.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.120.258814
- By:
- Publication type:
- Article
GRPr antagonist <sup>68</sup>Ga-SB3 PET/CT-imaging of primary prostate cancer in therapynaive patients.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 7, p. 1, doi. 10.2967/jnumed.120.258814
- By:
- Publication type:
- Article
GRPr antagonist <sup>68</sup>Ga-SB3 PET/CT-imaging of primary prostate cancer in therapynaive patients.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 6, p. 1, doi. 10.2967/jnumed.120.258814
- By:
- Publication type:
- Article
Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2021, v. 48, n. 5, p. 1339, doi. 10.1007/s00259-020-05057-6
- By:
- Publication type:
- Article
GRPr antagonist <sup>68</sup>Ga-SB3 PET/CT-imaging of primary prostate cancer in therapynaive patients.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 5, p. 1, doi. 10.2967/jnumed.120.258814
- By:
- Publication type:
- Article
Development of [ 225 Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC.
- Published in:
- Pharmaceutics, 2021, v. 13, n. 5, p. 715, doi. 10.3390/pharmaceutics13050715
- By:
- Publication type:
- Article
Autoradiographical assessment of inflammation-targeting radioligands for atherosclerosis imaging: potential for plaque phenotype identification.
- Published in:
- EJNMMI Research, 2021, v. 11, n. 1, p. 1, doi. 10.1186/s13550-021-00772-z
- By:
- Publication type:
- Article
Imaging of inflammatory cellular protagonists in human atherosclerosis: a dual-isotope SPECT approach.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2020, v. 47, n. 12, p. 2856, doi. 10.1007/s00259-020-04776-0
- By:
- Publication type:
- Article
In Vivo Evaluation of Indium-111-Labeled 800CW as a Necrosis-Avid Contrast Agent.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Maintaining radiochemical purity of [<sup>177</sup>Lu]Lu-DOTA-PSMA-617 for PRRT by reducing radiolysis.
- Published in:
- Journal of Radioanalytical & Nuclear Chemistry, 2019, v. 321, n. 1, p. 285, doi. 10.1007/s10967-019-06573-y
- By:
- Publication type:
- Article
Radiochemical and analytical aspects of inter-institutional quality control measurements on radiopharmaceuticals.
- Published in:
- EJNMMI Radiopharmacy & Chemistry, 2019, v. 4, n. 1, p. 1, doi. 10.1186/s41181-018-0052-1
- By:
- Publication type:
- Article
In Vivo Stabilized SB3, an Attractive GRPR Antagonist, for Pre- and Intra-Operative Imaging for Prostate Cancer.
- Published in:
- 2018
- By:
- Publication type:
- journal article
SSTR-Mediated Imaging in Breast Cancer: Is There a Role for Radiolabeled Somatostatin Receptor Antagonists?
- Published in:
- Journal of Nuclear Medicine, 2017, v. 58, n. 10, p. 1609, doi. 10.2967/jnumed.116.189035
- By:
- Publication type:
- Article
In Vitro comparison of <sup>213</sup>Bi- and <sup>177</sup>Lu-radiation for peptide receptor radionuclide therapy.
- Published in:
- PLoS ONE, 2017, v. 12, n. 7, p. 1, doi. 10.1371/journal.pone.0181473
- By:
- Publication type:
- Article
<sup>68</sup>Ga/<sup>177</sup>Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology.
- Published in:
- Journal of Nuclear Medicine, 2017, v. 58, n. 2, p. 293, doi. 10.2967/jnumed.116.176636
- By:
- Publication type:
- Article
Improved safety and efficacy of Bi-DOTATATE-targeted alpha therapy of somatostatin receptor-expressing neuroendocrine tumors in mice pre-treated with l-lysine.
- Published in:
- EJNMMI Research, 2016, v. 6, n. 1, p. 1, doi. 10.1186/s13550-016-0240-5
- By:
- Publication type:
- Article
Evaluation of a Fluorescent and Radiolabeled Hybrid Somatostatin Analog In Vitro and in Mice Bearing H69 Neuroendocrine Xenografts.
- Published in:
- Journal of Nuclear Medicine, 2016, v. 57, n. 8, p. 1289, doi. 10.2967/jnumed.115.164970
- By:
- Publication type:
- Article
Optimizing labelling conditions of <sup>213</sup>Bi-DOTATATE for preclinical applications of peptide receptor targeted alpha therapy.
- Published in:
- EJNMMI Radiopharmacy & Chemistry, 2016, p. 1, doi. 10.1186/s41181-016-0014-4
- By:
- Publication type:
- Article
Investigation of Factors Determining the Enhanced Permeability and Retention Effect in Subcutaneous Xenografts.
- Published in:
- Journal of Nuclear Medicine, 2016, v. 57, n. 4, p. 601, doi. 10.2967/jnumed.115.166173
- By:
- Publication type:
- Article
Comparison of the Therapeutic Response to Treatment with a <sup>177</sup>Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models.
- Published in:
- Journal of Nuclear Medicine, 2016, v. 57, n. 2, p. 260, doi. 10.2967/jnumed.115.167007
- By:
- Publication type:
- Article
Influence of tumour size on the efficacy of targeted alpha therapy with Bi-[DOTA,Tyr]-octreotate.
- Published in:
- EJNMMI Research, 2016, v. 6, n. 1, p. 1, doi. 10.1186/s13550-016-0162-2
- By:
- Publication type:
- Article
Preclinical Comparison of Al<sup>18</sup>F- and <sup>68</sup>Ga-Labeled Gastrin-Releasing Peptide Receptor Antagonists for PET Imaging of Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2014, v. 55, n. 12, p. 2050, doi. 10.2967/jnumed.114.141143
- By:
- Publication type:
- Article
Increased physical activity severely induces osteoarthritic changes in knee joints with papain induced sulphate-glycosaminoglycan depleted cartilage.
- Published in:
- Arthritis Research & Therapy, 2014, v. 16, n. 1, p. 1, doi. 10.1186/ar4461
- By:
- Publication type:
- Article